Tracheal terminal cells of Drosophila are immune privileged to maintain their Foxo-dependent structural plasticity Authors: Judith Bossen, Larissa Fritz, Reshmi Raveendran, Leizhi Shi, Jingjing He, Thomas Roeder, Jiwon Shim, Judith M Bossen, Larissa Fritz, Reshmi Raveendran, Leizhi Shi, Jingjing He, Thomas Roeder Published: 2026 ABSTRACT Respiratory organs must balance their primary function of gas exchange with the constant threat of inhaled pathogens. In the Drosophila tracheal system, gas exchange occurs at the tracheal terminal cells (TTCs), the functional equivalents of mammalian alveoli. While bacterial infection triggers a robust innate immune response throughout the broader airway epithelium, we reveal that TTCs are uniquely exempt from this reaction. Mechanistically, TTCs lack expression of the membrane-associated peptidoglycan recognition receptor PGRP-LC. This absence protects these highly susceptible cells from immune deficiency (Imd) pathway activation and subsequent JNK-mediated cell death, establishing TTCs as a distinct, immune-privileged niche. Ectopic immune activation via targeted PGRP-LCx overexpression in TTCs caused a severe reduction in branching, cellular damage, and ultimately cell death, phenotypes that were fully rescued by the depletion of AP-1 or foxo. Because both structural plasticity (in response to nutritional cues and hypoxia) and innate immune responses strictly require the transcription factor FoxO, we demonstrate that potent immune signaling is fundamentally incompatible with dynamic TTC remodeling. Ultimately, the immune-privileged status of TTCs represents an essential evolutionary trade-off, restricting local inflammation to preserve foxo-dependent structural plasticity and vital respiratory function. Introduction The tracheal system of Drosophila comprises three different parts: the main dorsal trunks, the smaller tracheal branches, and the terminal cells (Whitten, 1957; Uv et al., 2003). The tracheal terminal cells (TTCs) form the most distal part of the respiratory system. They are the site at which gas exchange takes place. TTCs fulfill an essential role by supplying all body organs with oxygen. To fulfill their task, even under ever-changing conditions, these cells possess a high degree of structural plasticity. For example, TTCs can sprout in response to local hypoxia (Jarecki et al., 1999), or in response to differences in nutrient availability (Centanin et al., 2010); this process is analogous to angiogenesis in mammals. Sprouting is dependent on growth factors, as well as the hypoxia-inducible factor (HIF)-α homolog sima, again analogous to endothelial cells during angiogenesis in the mammalian vascular system (Jarecki et al., 1999; Centanin et al., 2008; Horowitz and Simons, 2008). The primary role of the proximal tracheal tubes is to conduct air to more distal parts. The epithelial cells lining these tubes can mount an effective immune response to infections (Wagner et al., 2008; Faisal et al., 2014). This immune response is driven mainly by expression of several antimicrobial peptides (AMP) (Tzou et al., 2000; Akhouayri et al., 2011). One out of the two major immune pathways operative in Drosophila, the immune deficiency (Imd) pathway, is solely responsible for responses in the larval airway epithelium; this is because the Toll pathway is not functional in these cells (Wagner et al., 2008) Klicken oder tippen Sie hier, um Text einzugeben. The Imd signaling pathway is homologous to the human tumor necrosis factor-α (TNF-α) pathway and converges on activation of NF-κB factors. Moreover, it is connected to c-Jun N-terminal kinase (JNK) signaling via transforming growth factor-β (TGF-β) activated kinase 1 (dTak1) (Silverman et al., 2003). Infection of the airway system induces an immune response by the tracheal epithelium, which includes expression of canonical Imd and JNK target genes (Tzou et al., 2000; Wagner et al., 2009). Chronic activation of tracheal immune signaling leads to marked structural changes in the epithelium (Wagner et al., 2021). This tissue remodeling is mediated by JNK and its downstream transcription factor, forkhead box sub-group O (foxo), which is a terminal target of the epithelial immune system. FoxOs are also central proteins of the insulin signaling pathway, which also plays an important role in the structural plasticity of TTCs (Linneweber et al., 2014; Wong et al., 2014; Burguete et al., 2019). The present study shows that TTCs differ fundamentally from the rest of the tracheal epithelium. In the case of a natural infection of the tracheal system, these cells show only a negligible immune response. The very few TTCs that do show AMP expression are structurally impaired. We found that TTCs are immune privileged. The Imd pathway in TTCs is deactivated since the cells do not express the transmembrane peptidoglycan recognition protein (PGRP)-LCx. Chronic activation of the Imd signaling pathway in TTCs leads to JNK-dependent apoptosis. Therefore, we hypothesize that the immune privileged status of TTCs maintains the normal function of foxo, which acts as a regulator of structural plasticity. Results Tracheal infection revealed that AMP expression in terminal cells is rare Larvae carrying reporters for AMP genes were studied following infection with Pectobacterium carotovorum (formerly Erwinia carotovora) or under control conditions. These larvae express GFP under the control of promoters for different AMP genes, which are known to be activated by a natural infection in different tissues (Tzou et al., 2000). GFP fluorescence was analyzed after 24 h, focusing on the TTCs (Figure 1). Without infection AMP expression was rarely or never observed in the tracheal system (Figure 1A–E). Expression in the TTCs was never observed. In infected animals, AMP expression was observed frequently in the tracheal system, but again, never in the TTCs (Figure 1A'–E'). The emergence of AMP expression was quantified by counting the number of animals with fluorescence in the third tracheal metamere with focus on the dorsal part, especially in the dorsal branch/fusion cells (Figure 1F; GFP+, light green) and fluorescence in the TTCs (GFP TTCs, dark green). In 5–33% of the larvae, fluorescence was detected in the dorsal branch (DB)/fusion cell (FC) region; this number increased after infection to 24–70% (Figure 1G). But infection could not trigger an AMP response in the TTCs. In addition to a response in the trachea, fluorescence was observed in various tissues, such as hemocytes and fat body, especially in the anterior part, indicating the animals' general responsiveness to infection (Figure 1—figure supplement 1A–D). Terminal tracheal immune reaction to natural infection measured via AMP reporter response. GFP reporter larvae were infected (inf) with P. carotovorum for 24 h, and GFP fluorescence in the terminal structures of the tracheal system was monitored. The images were taken in the DIC and GFP channels. Scale, 50 µm. (A–E) Dorsal tracheal structures of non-infected larvae. (A'–E') Dorsal tracheal structures of infected larvae. (F) Dorsal view of the tracheal system, showing the dorsal trunks branching into the dorsal branch (DB), fusion cells (FC), and the dorsal TTCs. The quantification explanation is shown in magnification emphasized with colors. Presence of fluorescence in DB/FC counts as a GFP positive larva (light green, GFP+). Presence of fluorescence in the TTCs in GFP+ animals is indicated by dark green color (GFP TTCs). (G) Proportion of animals with tracheal fluorescence following the mentioned quantification procedure. Number above bars = number of tested animals. Scale bar, 50 µm. Drs = Drosomycin, Def = Defensin, Att = Attacin, Mtk = Metchnikowin, Dpt = Diptericin. Figure 1—figure supplement 1.AMP expression in infected larvae.GFP reporter larvae were infected with P. carotovorum for 24 h, and GFP fluorescence was monitored. Dr’s expression was visible in various larval structures, such as hemocytes and the fat body (A–D). Scale bar, 50 µm. Drs = Drosomycin, Def = Defensin, Mtk = Metchnikowin, Dpt = Diptericin. AMP expression in infected larvae. GFP reporter larvae were infected with P. carotovorum for 24 h, and GFP fluorescence was monitored. Dr’s expression was visible in various larval structures, such as hemocytes and the fat body (A–D). Scale bar, 50 µm. Drs = Drosomycin, Def = Defensin, Mtk = Metchnikowin, Dpt = Diptericin. For a more detailed analysis, we focused on the AMP Drosomycin (Drs), which showed the strongest response to infection in the trachea. A total of 169 infected larvae were examined over all tracheal metameres. About 34% showed no GFP signal in the focus area, a finding consistent with previous observations (Akhouayri et al., 2011). The remaining larvae showed a GFP signal in the DB/FCs (57.4%, Figure 2A and A'). The absence of a response in the TTCs was not limited to the dorsal TTCs but was also observed in TTCs supplying other body parts (Figure 2B). However, 8.3% showed Drs expression in TTCs (Figure 2C–G). Most of the few fluorescent TTCs showed clear structural differences from TTCs without a GFP signal (Figure 2D and D'). Although some cells had a normal structure (Figure 2E and E'), most had shortened branches (Figure 2D, D', F and F'), showed signs of melanization (Figure 2G, arrow), or were no longer air-filled (Figure 2G, arrowhead). These observations suggest an immune-triggered response in the TTC itself that acts negatively on these cells. Tracheal terminal cells (TTCs) show very rare Drs expression upon natural infection. Drs-GFP larvae were infected with P. carotovorum for 24 h, and GFP fluorescence in the TTCs of the tracheal system was monitored. Images were taken in the DIC (A, C–G) and GFP channels (A', C'–F'). (A) Dorsal TTCs without fluorescence. (B) Visceral TTCs without fluorescence. (C) Percentage of larvae showing GFP fluorescence in the DB and TTCs. Number above bar = number of tested animals. (D–G) TTCs with expression of Drs-GFP. White arrows indicate shortened TTC branches (G). The black arrows mark a melanization site, and the arrowhead marks a translucent branch without air filling (G). Dashed lines represent the proximal end of the TTCs. Scale bar, 50 µm. Tracheal terminal cells do not express the Imd-pathway receptor PGRP-LCx We wondered whether constitutive immune activation within the tracheal system would exclude TTCs, as expected from the results of the infection experiments. To ensure that all parts of the tracheal epithelium, including TTCs, were exposed to this activating stimulus, we ectopically expressed the secreted (and intracellular) Imd pathway receptor PGRP-LE using the ppk4-Gal4 driver. AMP expression (a readout of the immune response) was visualized by simultaneous expression of GFP-tagged Drs (Figure 3). A strong immune response was observed in the tracheal tissue, from the dorsal trunks down to the smaller branches (Figure 3A–C). While expression of Drs was consistent throughout most parts of the tracheal system, it was absent from the most distal parts (Figure 3B–E). Closer observation of the TTCs revealed a distinct breakpoint in the GFP signal at the proximal end of the TTCs. This was true for TTCs attached to the outer cuticle (Figure 3D) as well as for cells attached to the intestine (Figure 3E). Activation of the Imd pathway may not be fully functional in these cells. We infected the animals and quantified the corresponding response in the third tracheal metamere. We observed an increased response upon infection and a few fluorescence events in the TTCs in 3% of the animals (Figure 3F and G). Tracheal terminal cells (TTCs) do not express the Imd receptor PGRP-LCx. (A–D) The secreted Imd pathway receptor PGRP-LE is expressed in the main parts of the tracheal system (ppk4>PGRP-LE (GFP-Drs)). The arrows indicate TTCs not expressing GFP. The dashed lines represent the proximal end of the TTC. (A–C) An activated immune response in the larvae is visualized by expression of GFP-tagged Drosomycin (Drs). (D, E) Detailed TTCs were observed in fillet preparations (D) and in the dissected intestine (E) in both the DIC (D, E) and GFP channels (D', E'). (F) Example TTC of infected PGRP-LE animals with fluorescence. (G) Percentage of PGRP-LEOE animals with tracheal GFP expression (ctrl = control, inf = infected). Number above bars = number of tested animals. (H, I) Expression of GFP under the control of a PGRP-LCx promoter (PGRP-LCx-Gal4>UAS-GFP) revealed a lack of promoter activity and expression of GFP in TTCs on the cuticle (H, H') and intestine (I, I'), which is in contrast to the rest of the tracheal system. (J, K) The TTCs in the tracheal system are visualized by GFP expression in the cuticle (J) and intestine (K) of wild-type larvae (btl-Gal4; UAS-GFP). (L) Percentage of PGRP-LCx animals with tracheal GFP expression (ctrl = control, inf = infected). Scale bar, 50 µm. Dashed lines represent the proximal end of the TTCs. dt = dorsal trunk. To activate the Imd pathway successfully, secreted PGRP-LE has to bind to transmembrane PGRP-LC, meaning that only cells expressing PGRP-LC can be activated (Takehana et al., 2002; Takehana et al., 2004). Therefore, to investigate PGRP-LC expression in the tracheal system, specifically in TTCs, we expressed Gal4 controlled by the PGRP-LC promoter to drive concurrent GFP expression (Figure 3H and I). While GFP was visible throughout the entire tracheal system, it was absent from all TTCs associated with the cuticle (Figure 3H and H') and intestine (Figure 3I and I'). To demonstrate that GFP expression can be visualized in TTCs, and that the lack of a signal was not an artifact, expression of GFP in TTCs was driven by the tracheal driver btl-Gal4 (btl-Gal4; UAS-GFP) (Figure 3J and K). TTCs on the dissected cuticle (Figure 3J) and on the intestine (Figure 3K) expressed GFP. Similarly, as before, we infected the PGRP-LCx-P-Gal4 larvae and observed an increased number of animals with fluorescence in the third metamere DB/FCs but no animals with fluorescence in the TTCs (Figure 3L). Thus, the data indicate that the lack of expression of the Imd-pathway receptor PGRP-LC in TTCs is responsible for the difference between TTCs and cells in the rest of the tracheal system. The observation that only 3% of the PGRP-LE expressing animals show Drs expression in the TTCs after infection (Figure 3F and G) opens up alternative modes of induction, including potential stress responses mediated through, e.g., Foxo activation. Ectopic activation of PGRP-LCx in the tracheal system leads to the death of TTCs To further investigate the effects of PGRP-LCx-mediated immune responses on the tracheal system, we expressed PGRP-LCx exclusively in TTCs (PGRP-LCxOE; Figure 4). We found that Imd-mediated immune activation was restricted to these cells, as indicated by concurrent expression of GFP. Compared with the widely branched and diversified TTCs in control samples (Figure 3A), PGRP-LCx-expressing TTCs showed a striking phenotype characterized by smaller TTCs with shortened terminal branches (Figure 4A and B). Measurement of TTC branches in PGRP-LCx-expressing larvae revealed a significant reduction in the number and length of branches compared with the controls (Figure 4C and D). While cells in the control had about 14 branches, with a total length of about 1550 µm, TTCs in PGRP-LCxOE (III) insects had seven branches at the most, and the length did not exceed 514 µm. This means that the branched surface of TTCs expressing PGRP-LCx was reduced to less than one-third of that in controls. Additionally, we tested another PGRP-LCx expressing line (PGRP-LCxOE (II), also used later for mechanistic evaluation). We could see a less severe but still prominent TTC-phenotype (Figure 4C and D). To prove the less severe phenotype, we drove PGRP-LCxOE (III) and (II) in the dorsal trunks of the trachea and compared the tracheal thickness (Figure 4—figure supplement 1A–D). The PGRP-LC-dependent epithelial thickness phenotype was shown in a previous study (Wagner et al., 2021). PGRP-LCxOE (III) produced a significantly increased thickening phenotype compared to PGRP-LCxOE (II) (Figure 4—figure supplement 1A–D). Expression of PGRP-LCx by tracheal terminal cells (TTCs) leads to size reduction and loss of functionality. (A, B) Dorsal TTCs in the control (A) and DSRF-driven overexpression of PGRP-LCx in TTCs (B). (C, D) Measurement and quantification of the number (C) and length (D) of branches (n=22–45). Data are presented as the mean ± SD. (E) The hypoxia sensitivity assay was conducted with control and PGRP-LCx-expressing third-instar larvae under hypoxic conditions (2–3% O2, n=11–14). Data are presented as the means ± SEM. Statistical significance was tested using the Mann–Whitney U test. *p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001. (F) Culture vials containing control, hid;rpr, and Tak1 larvae (DSRF >hid;rpr/Tak1) at 4 days post-oviposition. (G, H) Transmission light microscopy of dissected intestines from third-instar larvae (F, G) or second-instar larvae (H) with the connected TTCs of control (G) showing expression of hid;rpr (H) or PGRP-LCx (I). (J, K) Dissected intestines from control larvae (J) or larvae expressing PGRP-LCx in TTCs (K) were stained with an antibody specific for cleaved Drosophila Dcp-1 (purple) (I', J') and then counterstained to detect GFP (green). (I'', J'') Merged channels. Scale bars, 50 μm. Figure 4—figure supplement 1.PGRP-LCx-mediated epithelial thickening of the dorsal trunks.PGRP-LCx expression in the tracheal system was induced for 24 h in third-instar larvae. Epithelial thickness of control larvae (A, btl-Gal4, UAS-GFP; tub-Gal80ts >w1118) was compared to PGRP-LCxOE larvae with PGRP-LCx on the third chromosome (III, B, btl-Gal4, UAS-GFP; tub-Gal80ts >UAS-PGRP-LCx) and on the second chromosome (II, C). Epithelial thickness was quantified (D). Scale bar, 50 µm. Data are presented as the mean ± SD. Statistical significance was evaluated using an unpaired t-test, ****p<0.0001. PGRP-LCx-mediated epithelial thickening of the dorsal trunks. PGRP-LCx expression in the tracheal system was induced for 24 h in third-instar larvae. Epithelial thickness of control larvae (A, btl-Gal4, UAS-GFP; tub-Gal80ts >w1118) was compared to PGRP-LCxOE larvae with PGRP-LCx on the third chromosome (III, B, btl-Gal4, UAS-GFP; tub-Gal80ts >UAS-PGRP-LCx) and on the second chromosome (II, C). Epithelial thickness was quantified (D). Scale bar, 50 µm. Data are presented as the mean ± SD. Statistical significance was evaluated using an unpaired t-test, ****p<0.0001. Figure 4—figure supplement 2.Increase in apoptotic signaling in PGRP-LC overexpression.The influence of PGRP-LC overexpression on apoptotic cells was investigated using α\begin{document}$\alpha $\end{document}-Dcp1 staining. For the analysis, the eighth tracheal metamere of the controls (A; ppk4-Gal4>w1118 (ControlD), w1118>UAS-PGRP-LCx (ControlR)) and PGRP-LCOE (B; ppk4-Gal4>UAS-PGRP-LCx) were used. (C) Quantification was performed by measuring the fluorescence intensity and calculating the CTCF (corrected total cell fluorescence) of ControlD, ControlR, and PGRP-LCOE. The statistical significance was evaluated using the Mann–Whitney test. ****p<0.0001, ***p<0.001, ns = not significant. Scale bar, 50 µm. Increase in apoptotic signaling in PGRP-LC overexpression. The influence of PGRP-LC overexpression on apoptotic cells was investigated using α\begin{document}$\alpha $\end{document}-Dcp1 staining. For the analysis, the eighth tracheal metamere of the controls (A; ppk4-Gal4>w1118 (ControlD), w1118>UAS-PGRP-LCx (ControlR)) and PGRP-LCOE (B; ppk4-Gal4>UAS-PGRP-LCx) were used. (C) Quantification was performed by measuring the fluorescence intensity and calculating the CTCF (corrected total cell fluorescence) of ControlD, ControlR, and PGRP-LCOE. The statistical significance was evaluated using the Mann–Whitney test. ****p<0.0001, ***p<0.001, ns = not significant. Scale bar, 50 µm. Figure 4—figure supplement 3.Overexpression of PGRP-LE and infection increased hypoxia sensitivity.The influence of PGRP-LEOE and bacterial infection on hypoxia sensitivity was analyzed based on the escape response of third-instar larvae exposed to 2.5% O2. Control: w1118>UAS-PGRP-LE (Drs-GFP), PGRP-LE overexpression: Btl-Gal4;Gal80>UAS-PGRP-LE (Drs-GFP). Six independent replicates, each with 10 larvae of the control (gray), infected control (black), PGRP-LEOE (pink), and infected PGRP-LEOE (burgundy) were used for quantification. Values are presented as mean ± SEM. Statistical analysis was performed using two-way ANOVA. **p<0.01, *p<0.1. Overexpression of PGRP-LE and infection increased hypoxia sensitivity. The influence of PGRP-LEOE and bacterial infection on hypoxia sensitivity was analyzed based on the escape response of third-instar larvae exposed to 2.5% O2. Control: w1118>UAS-PGRP-LE (Drs-GFP), PGRP-LE overexpression: Btl-Gal4;Gal80>UAS-PGRP-LE (Drs-GFP). Six independent replicates, each with 10 larvae of the control (gray), infected control (black), PGRP-LEOE (pink), and infected PGRP-LEOE (burgundy) were used for quantification. Values are presented as mean ± SEM. Statistical analysis was performed using two-way ANOVA. **p<0.01, *p<0.1. To investigate whether this cellular phenotype has an impact on physiological oxygen supply, we exposed larvae to low oxygen levels (2–3%). Leaving the lawn under hypoxic conditions is the normal response of larvae, and this response can be monitored over time. A significantly higher percentage of larvae with TTCs overexpressing PGRP-LCx showed the escape phenotype after 15–25 min of exposure (Figure 4E, Figure 4—figure supplement 3). Activation of the Imd pathway by ectopic expression of PGRP-LCx clearly impairs TTCs, not only with respect to size reduction, but also to the functionality of these cells (i.e., the enhanced response to hypoxic conditions). To elucidate whether this size reduction is part of an apoptotic cell program, we analyzed expression of two apoptotic factors: head involution defective (hid) and reaper (rpr) (White et al., 1994; Grether et al., 1995). We targeted expression of these factors to TTCs using the DSRF-Gal4 driver line. Larvae expressing hid; rpr showed a strong response to hypoxia by leaving the lawn at the very early larval stages; these larvae did not survive (Figure 4F). Since PGRP LCx-expressing larvae survived and did not show this extreme phenotype, we examined Tak1 (a downstream component of the Imd pathway). Expression of Tak1 in TTCs also resulted in early larval death, similar to expression of hid; rpr (Figure 4F). Dissection of hid; rpr-expressing insects revealed a complete absence of TTCs, with only rudimentary cell remnants connected to the intestine (Figure 3G and H). By contrast, overexpression of PGRP-LCx in TTCs resulted in similar cellular alterations, although the cells remained alive. Nevertheless, the overall phenotype was strikingly similar to that of apoptotic terminal cells (Figure 4I). Drosophila death caspase-1 (Dcp-1) is orthologous to mammalian Caspase-3, and is an established marker of apoptosis (21). Immunohistochemical analysis using an anti-Dcp-1 antibody (Figure 4J and K) revealed a lack of Dcp-1 in the control; however, strong GFP staining of TTCs was visible (Figure 4J–J''). TTCs expressing PGRP-LCx were positive for cleaved Dcp-1, whereas counterstaining for GFP revealed reduced expression (Figure 4K–K''). These data could indicate that TTCs are undergoing apoptosis in consequence of PGRP-LCx overexpression. To complete our results, we stained trachea with PGRP-LCx expression in the tracheal epithelium and saw an increase of cleaved Dcp-1 in these tracheae as well (Figure 4—figure supplement 2). We expressed PGRP-LE in the trachea for only 24 h to induce a mild activation of the pathway in TTCs and epithelial cells (using btl-Gal4; tubGal80ts) and compared hypoxia response under control and infected conditions (Figure 4—figure supplement 3). While we saw the same increase in the escape response of PGRP-LE larvae under control conditions, the response was even more enhanced for the infected larvae. PGRP-LCx-induced terminal cell death is mediated by JNK signaling The Drosophila Imd signaling pathway, which classically leads to activation of the NF-κB factor Relish, is homologous to the TNF-α signaling pathway in mammals. Like the TNF-α pathway, the Imd pathway branches out to the JNK signaling pathway; the branch point is Tak1 (Figure 5A). To test whether the NF-κB or the JNK branch is necessary to translate PGRP-LCx activation in TTCs into triggering of apoptosis, we expressed these downstream components in flies, which were then phenotyped. The number and length of the terminal branches were measured and compared with those in control TTCs, and with the phenotype produced by PGRP-LCx expression (Figure 5B–F). Ectopic expression of an activated Relish allele had no effect on the TTC branching phenotype (Figure 5B, E and F). Expression of a constitutively active form of dJNKK, hemipterous (hepCA), resulted in a phenotype like that caused by expression of the upstream receptor PGRP-LCx (Figure 5C, E and F). Branching of TTCs was reduced significantly and did not differ significantly from that of TTCs with PGRP-LCx expression. Overexpression of the wild-type JNK, basket (bskOE), also resulted in reduced branching when compared with the control (Figure 5D–F). These results suggest that JNK activation is responsible for the TTC phenotype. To further support this hypothesis, the cells were stained for the NF-κB factor Relish (Rel) and for the phosphorylated JNK (pJNK) basket (Figure 5G and H). JNK signaling is associated with impaired tracheal terminal cell (TTC) branching. (A) Schematic showing how the PGRP-LC-activated Imd signaling pathway is subdivided into the NF-κB (Relish) and JNK (hep = JNKK, bsk = JNK) pathways. (B–D) Relish (B, Rel68), as well as constitutively active hep (C, hepCA) and bsk (D, bskOE), were expressed in TTCs (DSRF >). (E, F) Measurement and quantification of the number (E) and length (F) of branches in control (w1118) versus PGRP-LCx-expressing TTCs (n=22–45). Data are presented as the mean ± SD. Statistical significance was evaluated using Mann–Whitney U test, **p<0.01, ****p<0.0001, ns = not significant. (G, H) Dissected intestines from control (DSRF >w1118) and PGRP-LCx-expressing flies (DSRF >PGRP-LCx), in which the TTCs were stained to detect Relish (Rel, G) and pJNK (purple, H). TTCs were counterstained with GFP (green). Arrows mark the TTC nucleus. Merged channels are shown. Scale bars, 50 µm. Staining of the transcription factor Relish was observed throughout intestinal tissue, as well as in TTCs, from controls, and in TTCs expressing PGRP-LCx; however, we observed no translocation of Relish to the nucleus (Figure 5G, arrow). In contrast to controls, PGRP-LCx-expressing cells showed distinct nuclear staining by an anti-pJNK antibody (Figure 5H, arrow). Moreover, nuclear pJNK was also observed in the nuclei of subjacent intestinal cells. This suggests that intestinal cells experience some additional JNK-mediated stress. JNK-mediated TTC damage can be rescued by AP-1 and foxo depletion The Drosophila JNK signaling pathway induces apoptosis (Adachi-Yamada et al., 1999; Takatsu et al., 2000). The canonical transcription factors (TFs) AP-1, foxo, and Ets21C act downstream of Tak1 and JNK to initiate transcription of target genes (Figure 6A). Activation of each of these factors can lead to expression of apoptotic genes (Hafezi et al., 1997; Lehmann et al., 2002; Luo et al., 2007; Mundorf et al., 2019). To evaluate whether one of these TFs is responsible for the PGRP-LCxOE-induced phenotype, we silenced each of them. This experimental approach required the use of different controls with the PGRP-LCxOE cassette located on different chromosomes. Beside the PGRP-LCxOE (III) on the third chromosome, we used PGRP-LCxOE (II), which produces a less severe phenotype and is located on the second chromosome (Figure 6F and G; red and blue). First, we used a dominant-negative form of Tak1 (Tak1DN) and bsk (bskDN) together with PGRP-LCxOE to confirm that PGRL-LC-induced apoptosis of TTCs is mediated by JNK. Concurrent expression of PGRP-LCxOE with either Tak1DN or bskDN rescued the apoptotic phenotype (Figure 6B, F and G). Fos and Jun proteins form homo- or heterodimers that act as AP-1 transcription factors, also a canonical target of the JNK pathway. To target AP-1, we focused on the Drosophila Fos ortholog kayak (kay). We co-expressed a dominant-negative kay allele (kayDN) together with PGRP-LCxOE in TTCs. Although kayDN rescued the PGRP-LCxOE phenotype with respect to the number and length of branches, it was not complete (Figure 6C, F and G; red). Co-expression of foxoRNAi rescued the PGRP-LCxOE phenotype to the same level as kayDN (Figure 6D, F and G; red). RNAi of Ets21C failed to rescue the PGRP-LCxOE phenotype (Figure 6E–G; blue); rather, it worsened the phenotype with respect to the length of branches. The tracheal terminal cell (TTC) phenotype induced by PGRP-LCx is dependent on the transcription factors kay and foxo. (A) Schematic illustration of the JNK signaling pathway downstream of Tak1, which includes Ets21C, kay, and Jra (AP1). (B–E) DSRF-driven PGRP-LCxOE in TTCs was combined with the dominant-negative form of Tak1, bsk (B), and kay (C), or with RNAi targeting foxo (D) or Ets21C (E). (F, G) Measurement and quantification of the number (F) and length (G) of branches (n=16–45). (H–K) Measurement and quantification of the number (H) and length (I) of GFP-expressing branches in control (w1118) and PGRP-LCx-expressing cells (n=7–45). TTCs overexpressing foxo (J, foxoOE), and kay and Jra (K, kayOE +JraOE). (L, M). TRE-RFP expression in control (L) and PGRP-LCx-expressing TTCs (M). (N) Foxo promoter activity in TTCs (foxo-Gal4>UAS-GFP). Data are expressed as the mean ± SD. Statistical significance was evaluated using Mann–Whitney U test, * p<0.05, ***p<0.001, ****p<0.0001, ns = not significant. The color of the asterisk indicates the corresponding comparison. Dashed lines represent the mean control value. Scale bar, 50 µm. Because depletion of the TFs foxo and kayak rescued the TTC phenotype induced by PGRP-LCx overexpression, we next tested whether upregulation of either induces a similar TTC phenotype (Figure 6H–K). Overexpression of foxo led to a slight reduction in the number and length of the branches (Figure 6H–J), while overexpression of a combination of kay and Jra, which drives concurrent overexpression of both AP-1 components, led to a severe reduction in number and length of the branches, to levels below that induced by PGRP-LCx overexpression (Figure 6H–J and K). Therefore, we asked whether foxo and AP-1 are present and active in TTCs. To do this, we used an AP-1 responsive TRE-RFP reporter line to detect AP-1 activity in TTCs (Chatterjee and Bohmann, 2012). We observed AP-1 activity in wild-type TTCs, and upon overexpression of PGRP-LCx (Figure 6L and M). When we used a Gal4 line with a foxo promoter, we observed strong foxo promoter activity in all TTCs (Figure 6N). Thus, both TFs appear to be expressed and functional in TTCs. Foxo controls TTC branching under normal conditions and under conditions of oxygen deprivation A previous study reported a role for foxo in maintaining homeostasis of tracheal epithelial cells (Wagner et al., 2021). One of the main features that ensures full functionality of TTCs under changing conditions is the ability to adapt to local hypoxia to maintain the supply of oxygen to target tissues; therefore, we subjected wild-type larvae and larvae with foxo-RNAi in TTCs to mild hypoxia (5% O2) and measured their branching ability (Figure 7). As expected, wild-type TTCs responded with increased branching (Figure 7A, B and E). The foxoRNAi TTCs already had an increased number of branches under control conditions (21% O2; Figure 7C–E), and the number of branches did not increase further after oxygen deprivation; this suggests that foxo is required for appropriate responses to hypoxic conditions (Figure 7D and E). Targeted reduction of foxo expression in tracheal terminal cells (TTCs) leads to hyperbranching. (A, B) Representative tracheal branching in control (A) and DSRF-driven foxoRNAi (B) cells under normoxic conditions. (C, D) Representative images showing tracheal branching in control (C) and foxORNAi (D) cells under hypoxic conditions. (E) Quantification of branches in control and DSRF >foxORNAi TTCs under normoxic (21%) and hypoxic (5%) conditions. Scale bar, 50 µm. n=21, Data are presented as the mean ± SD. Statistical significance was evaluated using Mann–Whitney U t-test, *p<0.05, ****p<0.0001, ns = not significant. In summary, the data suggest that TTCs differ from the other parts of the tracheal system in terms of immune pathway activation (Imd/JNK); this is a mechanism that circumvents cell death and prevents impairment of functionality (Figure 8A). The Imd pathway receptor PGRP-LCx does not appear to be expressed in TTCs, indicating that no downstream signaling takes place (Figure 8B). Ectopic expression of PGRP-LCx exclusively in these cells leads to JNK-mediated cell death; however, all downstream components must be present and functional. We have shown that depletion of the JNK-associated TFs AP-1 and foxo can rescue the PGRP-LCx-mediated phenotype. Both are present under physiological conditions, and their overexpression can induce a severe TTC phenotype. In addition, the universal transcription factor foxo, which is not only associated with JNK signaling, plays a role in branching of TTCs under normal and hypoxic conditions, indicating its importance for TTC homeostasis. Schematic summarizing the JNK-mediated immune/stress response in the trachea and tracheal terminal cells (TTCs). (A) Tracheal infection leads to an immune response involving expression of antimicrobial peptides such as Drosomycin (Drs, green). In most cases, the immune response is restricted to the tracheal trunks and the TTCs are unaffected (bold arrow). In rare cases, TTCs express Drs, resulting in an impaired phenotype (dashed arrow). (B) Imd signaling in the main tracheal trunks is induced by peptidoglycan recognition receptors (PGRP)-LC and -LE. Downstream, the signaling branches into a Relish (Rel) and a JNK signaling pathway. Activation of the pathways mediates airway remodeling (13). However, activation in TTCs is avoided by the absence of PGRP-LC, even though all other JNK signaling pathway components are present. The pathway can be activated by external stressors, resulting in AP-1-mediated cell death. The transcription factor foxo, which is a component not only of the JNK signaling pathway but also of the insulin signaling pathway, plays a role in TTC homeostasis and their ability to branch. Discussion Activation of the immune system is a double-edged sword in that although it fights infection, it can also damage the organism’s tissues (Ruff et al., 2020); therefore, appropriate regulation and restriction of the immune system is of prime importance. Tight regulation of the immune system is essential when delicate, sensitive tissues are involved, or when immune-relevant signaling pathways are also needed for other cellular functions. Tracheal TTCs appear to fall into both categories; they are susceptible due to their specific structure but require foxo signaling to maintain structural plasticity. Here, we found that TTCs, in contrast to the other epithelial cells in the trachea, barely respond to bacterial infection. Immune-privileged status might protect TTCs from damage caused by a strong immune response, a strategy that also protects other organ systems (Galea et al., 2007; Forrester et al., 2008; Hill et al., 2021). Here, we found that the entire tracheal epithelium expressed the transmembrane receptor PGRP-LC, but not TTCs. We propose that the lack of PGRP-LCx expression by TTCs is the reason for their lack of an immune response. This hypothesis is supported by the observation that targeted overexpression of PGRP-LC in TTCs induced an immune response, suggesting that all other pathway components are active in these cells. Since targeted overexpression of PGRP-LC leads to degeneration and, ultimately, apoptosis of these cells, this finding is particularly interesting. Targeted induction of apoptosis in TTCs by hid and rpr induced a similar, but more severe, phenotype; indeed, these larvae die after complete ablation of the cells. The weaker phenotype we observe in PGRP-LCx expressing TTCs could be also explained by a non-apoptotic function of Dcp-1. Dcp-1 encodes for an effector caspase during the apoptotic process but does also have non-apoptotic functions. Dcp-1 is involved in autophagy regulation and mitochondrial morphology (Hou et al., 2009; DeVorkin et al., 2014). In our case, Dcp-1 is not only cleaved upon PGRP-LCx expression in the TTCs, but also in the tracheal epithelial cells. As described, PGRP-LCx expression in these cells does mediate tissue hyperplasia and renewal (Wagner et al., 2021). Furthermore, a role in inhibition of innate Toll signaling by cleavage of NF-κBs was reported (Wu et al., 2022). Herein, we show that (1) TTCs respond to a strong immune response by undergoing apoptosis, which leads to the death of the animal; and (2) that immune activation is prevented by a lack of expression of the central receptor of the Imd pathway, PGRP-LCx. To better understand the first finding, we needed to elucidate the mechanism of apoptosis induction on the one hand and to identify mechanisms that still protect against infection on the other. Activation of the Imd pathway by ectopic expression of PGRP-LCx throughout the trachea leads to JNK-dependent meta- and hyperplasia of the trunk cells (Wagner et al., 2021). The JNK pathway, as well as activation of its canonical TFs, is associated with both proliferation and apoptosis. The intertwining of the Imd pathway with the JNK pathway occurs at the level of Tak1 and is a general organizational principle within these signaling pathways. This architecture means that strong activation of the Imd pathway in these cells also triggers the multifaceted JNK pathway. Downstream of JNK (bsk in Drosophila), we found that foxo and AP-1 are both necessary and sufficient for the apoptotic phenotype in TTCs. AP-1 is a classical TF that is activated by JNK signaling. The reason underlying the incomplete rescue is unknown but might be due to a specific role for foxo in this context. We also demonstrated that depleting foxo rescues the apoptotic phenotype, at least in part. Although the effects triggered by foxo depletion or foxo overexpression were statistically significant, they were certainly not as strong as those triggered by AP-1. This difference in efficiency is because the tools used to manipulate foxo (RNAi and overexpression) are much weaker than those used to manipulate AP-1 signaling. For example, in the latter case, a dominant-negative form of kay and a fully active heterodimer of Jra and kay were available; in the case of foxo, the overexpression allele does not give rise to an activated version of foxo, and RNAi is generally less effective than dominant-negative alleles. In the tracheal cells of the dorsal trunk, and the primary and secondary branches, foxo plays a role in tracheal remodeling downstream of Imd pathway activation (Wagner et al., 2021). It seems reasonable then that foxo would also be activated in TTCs downstream of Imd signaling, which would in turn disrupt branching control and thus TTC functionality, as well as the ability to respond to environmental changes. Our central hypothesis derived from these observations is as follows: since foxo is essential for structural plasticity, and this property is critical for the survival of the organism, foxo should not be activated by other signals such as those from the Imd pathway. Foxo is activated not only by JNK signaling but also is a canonical member of the insulin signaling pathway. Linneweber and colleagues showed that insulin signaling, and especially the insulin receptor, is necessary for TTCs to respond (i.e., with reduced branching) to changing nutritional conditions such as low protein concentrations in food (Linneweber et al., 2014). Moreover, different insulin receptor alleles affect the size of TTCs (Burguete et al., 2019). Here, we showed that foxo is also part of this signaling pathway and that it is (presumably) required to translate different insulin signaling activities into structural changes in TTC branching. A very similar scenario for FoxO signaling is operative in endothelial cells (ECs). Insulin and VEGF signaling in human ECs targets FoxO to control its transcriptional activity directly via PI3K/Akt signaling (Abid et al., 2004; Abid et al., 2006). An alternative explanation for the observed lack of an immune response in TTCs could be their maximal distance from the spiracles. In this scenario, a gradient of bacterial inducers along the tracheal system might be expected, resulting in a gradual decrease in immune activation from the spiracles toward the TTCs. However, this is not what we observed. In tracheae that displayed an immune response, the response was largely homogeneous along the entire length of the tracheal system, from the spiracles to the TTCs. Only at the transition to the TTCs did the immune response drop abruptly. This observation argues against the gradient hypothesis and suggests that TTCs are specifically excluded from the immune response. Following our discussion of why it is sensible and necessary to omit this vital part of epithelial immunity from TTCs, we will focus on alternative strategies that operate to ensure that the cells are protected against infection. The strong immune response of the tracheal epithelium may be sufficient to protect the trachea, making an immune response in distant TTCs unnecessary. This strong and efficient immune response in the airway epithelia includes contact structures that connect the tracheal system with the outside world: the dorsal trunks and the primary and secondary branches (Wagner et al., 2008; Davis and Engström, 2012; League and Hillyer, 2016; Bossen et al., 2023). TTCs reside at the very ends of these systems, so potential pathogens would have to travel a long distance and escape powerful immune responses before reaching the TTCs. In addition, the diameters of 0.1–1 µm are so small that most bacteria will not gain access (Jarecki et al., 1999). The mechanisms underlying immune privilege vary. The same is true for the mechanisms that dampen the immune response. Here, we found that the dampening of the immune response was almost complete (based on non-expression of the proximal receptor within the canonical signaling pathway controlling epithelial immunity). A similar strategy was reported in a subpopulation of intestinal epithelial cells, called enterocytes, that do not express the Imd receptor PGRP-LCx (Fink et al., 2016). It was hypothesized that this prevents chronic MAMP-mediated activation of innate epithelial immune responses in these cells, which are constantly exposed to gut bacteria. Organs such as the liver, kidney, lymphoid organs, brain, and lung are immunotolerant (Amersfoort et al., 2022). Relevant immune pathways that induce apoptosis are dampened to different extents. In Drosophila epithelia, this dampening applies primarily to the Imd pathways because Toll signaling is not functional in these structures (Ferrandon et al., 1998; Wagner et al., 2008). Interestingly, the mammalian homolog of the Imd pathway, the TNF-α pathway, also invokes these protective strategies. This can be seen in ECs, which are the first cells to meet pathogens in the circulation and share some characteristics with TTCs. For example, they express several PRRs, as well as secrete pro-inflammatory cytokines to initiate immune responses (Mai et al., 2013). To prevent EC death and apoptosis, protective genes and negative feedback loops become active when immune pathways are triggered (Bach et al., 1997). For example, VEGF/VEGFR signaling is immunosuppressive (Yang et al., 2018) because it inhibits TNF-α induced apoptosis of ECs; VEGF inhibits secretion of TNF in a concentration-dependent manner (Spyridopoulos et al., 1997). For example, during angiogenesis and VEGFR activation, ECs express the anti-apoptotic gene surviving, which reduces caspase-3 activity and inhibits TNF-α-mediated apoptosis (O’Connor et al., 2000). The anti-apoptotic gene A20, when expressed in ECs, protects them from TNF-α-induced cell death, and inhibits inflammatory responses triggered by NF-κB activation (Daniel et al., 2004). Trabid, the equivalent of A20 in flies, is a negative regulator of the Imd signaling pathway (Fernando et al., 2014). TNF-α signaling, which induces death of various cell types, is a classical apoptotic pathway. TNF-α-induced apoptosis is highly regulated in ECs, which resist TNF-α-induced and physiological inflammatory apoptosis via TAK1 (Naito et al., 2019), which also regulates necroptosis and metastasis of ECs (Yang et al., 2019). A recent study from our lab shows an inability of TTCs to respond to low oxygen levels upon Trabid knockout, which supports our hypothesis that this signaling pathway converging onto foxo activation is necessary for this response (Bossen et al., 2025). The branching process in TTCs is comparable with that observed during angiogenesis, in which the outgrowth of new capillaries is regulated by VEGF/VEGFR signaling. Angiogenesis is influenced by events that induce survival or apoptosis in ECs; it can only be maintained by EC survival or inhibition of apoptosis mediated, for example, by growth factors such as VEGF/VEGFR and PI3K/Akt (Chavakis and Dimmeler, 2002). Expression of the Ig-family member CD31 by ECs prevents cell death and renders them immune privileged (Cheung et al., 2015). When the TNF-α pathway is activated in ECs, CD31 is also activated; this in turn activates the Erk/Akt pathway and subsequent exclusion of FoxO3 from the nucleus, leading ultimately to inhibition of apoptosis in vitro. FoxO factors play a central role in controlling cell fate (i.e., apoptosis or proliferation). Constitutively active FOXO3a promotes EC apoptosis by downregulating protective factors, whereas dominant-negative FoxO protects ECs from apoptosis (Skurk et al., 2004). In line with this observation, loss of mFoxO1 from murine ECs leads to uncontrolled overgrowth and hyperplasia. Moreover, FoxO controls endothelial quiescence by reducing glycolysis and mitochondrial respiration (Wilhelm et al., 2016). Active FoxO inhibits EC migration, whereas its silencing has the opposite effect (Potente et al., 2005). By coincidence, we discovered a similar role for foxo in Drosophila larval TTCs. We showed that foxo controls the branching of TTCs. Overexpression of foxo led to reduced branching, whereas foxo depletion increased TTC branching. We hypothesize that TTCs need to avoid activation of the Imd pathway because they depend on foxo to maintain full functionality in response to changing environmental conditions. The exact role of foxo in TTCs, and the signaling pathways involved, remain to be elucidated. Our study highlights the importance of Drosophila TTCs as a model for human ECs and thus may provide information that is useful for angiogenesis-related research. The data presented herein demonstrate how immune privilege is necessary to maintain the functionality of specific cell types. In the case of TTCs, which should mount potent immune responses, the architecture and interconnectivity of the Imd (TNF-α) and JNK pathways mean that cell fate is inevitably linked to foxo. This is, however, incompatible with the role of foxo in controlling the structure and functionality of these cells under changing conditions. For these reasons, switching off the Imd pathway is the only solution to this dilemma. Materials and methods Key resources tableReagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional informationGenetic reagent (Drosophila melanogaster)w1118Bloomington Drosophila Stock CenterRRID:BDSC_5905Genetic reagent (D. melanogaster)Drs-GFPBloomington Drosophila Stock Center; Tzou et al., 2000RRID:BDSC_55707FlyBase symbol: P{Drs-GFP.JM804}1Genetic reagent (D. melanogaster)Def-GFP Tzou et al., 2000 FlyBase ID: FBgn0010385Genetic reagent (D. melanogaster)AttGFP Tzou et al., 2000 FlyBase ID: FBgn0012042Genetic reagent (D. melanogaster)Mtk-GFP Tzou et al., 2000 FlyBase ID: FBgn0014865Genetic reagent (D. melanogaster)Dpt-Gfp Tzou et al., 2000 FlyBase ID: FBgn0004240Genetic reagent (D. melanogaster)PGRP-LCx-Gal4Bloomington Drosophila Stock CenterRRID:BDSC_77776FlyBase symbol: Mi{Trojan-GAL4.1}PGRP-LCMI06861-TG4.1Genetic reagent (D. melanogaster)UAS-GFPBloomington Drosophila Stock CenterRRID:BDSC_52262FlyBase symbol: P{20XUAS-6XGFP}attP2Genetic reagent (D. melanogaster)ppk4-Gal4 Liu et al., 2003b FlyBase ID: FBgn0024319Genetic reagent (D. melanogaster)btl-Gal4; tub-Gal80tsLeptin Group, EMBL HeidelbergFlyBase ID: FBgn0285896Genetic reagent (D. melanogaster)DSRF-Gal4 Gervais and Casanova, 2011 FlyBase ID: FBgn0004101Genetic reagent (D. melanogaster)UAS-PGRP-LCx (III)Kathryn Anderson, New YorkFlyBase ID: FBgn0035976Genetic reagent (D. melanogaster)UAS-PGRP-LCx (II)Bloomington Drosophila Stock CenterRRID:BDSC_30918FlyBase symbol: P{UAS-PGRP-LC.x}2Genetic reagent (D. melanogaster)UAS-PGRP-LEShoichiro Kurata, SendaiFlyBase ID: FBgn0030695Genetic reagent (D. melanogaster)UAS-Rel68Bloomington Drosophila Stock CenterRRID:BDSC_55777FlyBase symbol: P{UAS-FLAG-Rel.68}1Genetic reagent (D. melanogaster)UAS-Tak1Bloomington Drosophila Stock CenterRRID:BDSC_58810FlyBase symbol: P{UAS-Tak1.M}T8Genetic reagent (D. melanogaster)UAS-Tak1DNBloomington Drosophila Stock CenterRRID:BDSC_58811FlyBase symbol: P{UAS-Tak1.K46R.M}T4Genetic reagent (D. melanogaster)UAS-bskOEBloomington Drosophila Stock CenterRRID:BDSC_9310FlyBase symbol: P{UAS-bsk.B}2Genetic reagent (D. melanogaster)UAS-bskDNBloomington Drosophila Stock CenterRRID:BDSC_9311FlyBase symbol: P{UAS-bsk.K53R}20.1aGenetic reagent (D. melanogaster)UAS-kayDNBloomington Drosophila Stock CenterRRID:BDSC_7214FlyBase symbol: P{UAS-Fra.Fbz}5Genetic reagent (D. melanogaster)UAS-kayOEBloomington Drosophila Stock CenterRRID:BDSC_7213FlyBase symbol: P{UAS-kay.E}2Genetic reagent (D. melanogaster)UAS-JraOEBloomington Drosophila Stock CenterRRID:BDSC_7216FlyBase symbol: P{UAS-Jra}2Genetic reagent (D. melanogaster)UAS-foxoRNAiBloomington Drosophila Stock CenterRRID:BDSC_27656FlyBase symbol: P{TRiP.JF02734}attP2Genetic reagent (D. melanogaster)UAS-Ets21CRNAiBloomington Drosophila Stock CenterRRID:BDSC_39069FlyBase symbol: P{TRiP.HMS01989}attP2Genetic reagent (D. melanogaster)UAS-hid; rprChristian Wegener, WürzburgFlyBase ID: FBgn0003997, FBgn0011706Genetic reagent (D. melanogaster)TRE-RFP reporter Chatterjee and Bohmann, 2012 Genetic reagent (D. melanogaster)UAS-dTak1DN;UAS-PGRP-LCx-OEOtherCombination stock of UAS-Tak1DN and UAS-PGRP-LCx (III)(RRID:BDSC_58811), generated by crossing using a balancer stock.Genetic reagent (D. melanogaster)UAS-FoxORNAi; UAS-PGRP-LCx-OEOtherCombination stock of UAS-foxoRNAi (RRID:BDSC_27656) and UAS-PGRP-LCx (III), generated by crossing using a balancer stock.Genetic reagent (D. melanogaster)UAS-PGRP-LCx-OE; UAS-bskDNOtherCombination stock of UAS-PGRP-LCx (II) (RRID:BDSC_30918)and UAS-bskDN (RRID:BDSC_9311), generated by crossing using a balancer stock.Genetic reagent (D. melanogaster)UAS-kayDN; UAS-PGRP-LCx-OEOtherCombination stock of UAS-kayDN (RRID:BDSC_7214) and UAS-PGRP-LCx (III), generated by crossing using a balancer stock.Genetic reagent (D. melanogaster)UAS-PGRP-LCx-OE; UAS-Ets21cRNAiOtherCombination stock of UAS-kayDN (RRID:BDSC_7214) and UAS-PGRP-LCx (III), generated by crossing using a balancer stock.Genetic reagent (D. melanogaster)UAS-KayOE; UAS-JraOEOtherCombination stock of UAS-kayOE (RRID:BDSC_7213) and UAS-JraOE (RRID:BDSC_7216), generated by crossing using a balancer stockStrain, strain background (Pectobacterium carotovorum) Ecc-15, 2141Laboratory stockAntibodyAnti-Dcp-1 (rabbit polyclonal)Cell Signaling TechnologyCat# 9578RRID:AB_2721060Dilution: 1:100AntibodyAnti-pJNK (rabbit polyclonal)PromegaCat# V7931RRID:AB_430864Dilution: 1:300AntibodyAnti-Relish (mouse monoclonal)Developmental Studies Hybridoma Bank (DSHB)Cat# anti-Relish-C 21F3RRID:AB_1553772Dilution: 1:10AntibodyAnti-GFP (mouse monoclonal)Developmental Studies Hybridoma Bank (DSHB)Cat# DSHB-GFP-8H11RRID:AB_2617423Dilution: 1:200AntibodyGoat anti-rabbit IgG, AF488 (rabbit polyclonal)InvitrogenCat#A-11034Dilution: 1: 300AntibodyGoat anti-mouse IgG, AF 488 (mouse monoclonal)Jackson ImmunoResearch LabsCat# 115-545-003RRID:AB_2338840Dilution: 1:300AntibodyGoat anti-rabbit IgG, Cy3 (rabbit polyclonal)Jackson ImmunoResearch LabsCat# 111-165-003RRID:AB_2338000Dilution: 1:300AntibodyGoat anti-mouse IgG (mouse polyclonal)Jackson ImmunoResearch LabsCat#115-165-003RRID:AB_2338680Dilution: 1:300Software, algorithmImageJ (NeuronJ plugin)NIH; Meijering et al., 2004ImageJ (RRID:SCR_003070) NeuronJ (RRID:SCR_002074)Software, algorithmAxioVision SE64ZeissRRID:SCR_002677Software, algorithmGraphPad Prism (or equivalent)GraphPadRRID:SCR_002798Chemical compound, drugGoat SerumMerckCat#G9023OtherDAPICarl Roth GmbH & Co. KGCat# 6335.1Dilution: 1:2000All other chemicals or reagents were obtained from Carl Roth GmbH & Co. KG unless otherwise specified. All other chemicals or reagents were obtained from Carl Roth GmbH & Co. KG unless otherwise specified. Fly lines and husbandry Flies were raised on corn meal medium at 25°C. Tracheal humoral immune responses were tracked using Drs-GFP (BDSC_55707), which allows measurement of the GFP-tagged promoter activity of the AMP gene Drosomycin. Similar to this, we employed GFP reporters for Defensin, Attacin, Metchnikowin, and Diptericin (Tzou et al., 2000). The expression pattern of PGRP-LCx was analyzed by crossing PGRP-LCx-Gal4 (BDSC_77776) flies with UAS-GFP (BDSC_52262) flies. Tracheal driver lines ppk4-Gal4 (Liu et al., 2003a) and btl-Gal4; UAS-GFP (tub-Gal80ts) (Leptin Group, EMBL Heidelberg), or TTC driver line UAS-GFP; DSRF-Gal4 (Gervais and Casanova, 2011), were crossed to the corresponding responder lines UAS-PGRP-LCx(III) (Kathryn Anderson, New York), UAS-PGRP-LC(II) (BDSC_30918), UAS-PGRP-LE (Dipt.-lacZ,UAS-Flag-PGRP-LE/CyO, Shoichiro Kurata, Sendai), UAS-Rel68 (BDSC_55777), UAS-Tak1 (BDSC_58810), UAS-hid;rpr (UAS-hid; rpr; Christian Wegener, Würzburg), UAS-bskOE (BDSC_9310), TRE-RFP attP40 (Chatterjee and Bohmann, 2012), UAS-bskDN (BDSC_44801), UAS-kayDN (BDSC_7214), UAS-Ets21CRNAi (BDSC_39069), UAS-foxoRNAi (BDSC_27656), UAS-kayOE (BDSC_7213), and UAS-JraOE (BDSC_7216), or w1118 (for control crossing, BDSC_5905). Infection experiments Natural infection of larvae was performed as described (Tzou et al., 2000; Akhouayri et al., 2011). The gram-negative bacterium P. carotovorum (E. carotovora, Ecc-15, 2141) was cultured overnight at 30°C in LB broth. The bacteria were pelleted by centrifugation for 20 min at 3200×g, resuspended in PBS, and absorbance at OD600 measured. Next, 200 µl of the bacteria solution (OD600=160) was dropped into a vial containing developing second- or early third-instar larvae (3 days after egg laying) in standard cornmeal medium. After 24 h, the third-instar larvae were used for microscopy. The larvae were heat killed in a drop of glycerol at 70°C for 20–25 s and arranged on a microscopy slide with the dorsal side facing up. GFP expression in the tracheal DB and TTC between the dorsal trunks was analyzed. Branching analysis The third-instar larvae were washed in PBS and deposited on a slide in a drop of glycerol. The larvae were heat killed at 70°C for 20–25 s and arranged dorsal side up before microscopy. Images of the TTCs were taken using the GFP channel (at ×10 or ×20 magnification). The right TTC from the third dorsal segment was chosen for analysis. Images were taken by an Axio Imager.Z1 (Zeiss, Munich, Germany) with ApoTome in Z-stack mode to capture all TTC branches. Measurement of the number and length of TTC branches was undertaken using the ImageJ plugin NeuronJ (Meijering et al., 2004). The branches were measured, as described previously (Jones and Metzstein, 2011). Immunohistochemistry and microscopy For microscopic and immunohistochemical analyses of intestinal TTCs, the gut of third-instar larvae (along with the connected TTCs) was dissected. As an alternative, a fillet dissection for the cuticle-attached TTCs was used for microscopy. The tissue was dissected in PBS, fixed with 4% PFA, and blocked with 5% normal goat serum (Sigma-Aldrich, Munich, Germany) before overnight incubation at 4°C with an anti-GFP antibody (1:200, DSHB, Iowa City, USA). Cells were also stained with anti-Dcp-1 (1:200, Cell Signaling Technology, Danvers, USA), anti-pJNK (Promega, V7931), and anti-Relish-C (DSHB, 21F3). Images were taken with an Axio Imager.Z1 (Zeiss) with ApoTome in the Z-stack mode. Hypoxia sensitivity assay The third-instar larvae were washed with PBS and placed into a new food vial with a scratched surface; 20 larvae were used per replicate. The vials were incubated for at least 10 min until all larvae were buried in the food and then deposited in a sealed desiccator. Nitrogen gas was introduced until the O2 concentration reached 2–5%. This O2 level was maintained for 25 min. The number of larvae outside of the food was counted every 5 min. Measurement of epithelial thickness of the dorsal trunks For temporal control using the TARGET system, crosses (with btl-Gal4; UAS-GFP tub-Gal80ts) were maintained at 18°C (restrictive temperature) until larvae reached the third-instar stage. Larvae were then shifted to 29°C (permissive temperature) for 24 h to induce transgene expression. Late L3 wandering larvae were washed in PBS to remove residual food and dissected in PBS. Z-stack DIC and GFP images were acquired using an Axio Imager Z1 microscope equipped with ApoTome (Zeiss). Epithelial thickness was quantified using the AxioVision SE64 Rel. 4.9 software (Zeiss). Measurements were performed in the ninth tracheal metamere. This is a valuable report describing tracheal terminal cells (TTCs) in Drosophila as an immune-privileged organ. The authors demonstrated that TTCs lack expression of the membrane-associated peptidoglycan recognition receptor PGRP-LC, which protects these cells from immune pathway activation and JNK-mediated cell death to maintain TTC homeostasis. While the genetic experiments using RNAi and overexpression are convincing and solid, the broader biological significance of this phenomenon requires further investigation. This work will be of interest to researchers in innate immunity across various model systems. Summary: In their manuscript entitled "Terminal tracheal cells of Drosophila are immune privileged to maintain their Foxo-dependent structural plasticity", Bossen and colleagues determine that the terminal cells of the tracheal system differ from other larval tracheal cells in that they do not typically show an Imd-dependent immune response to fungal and viral infections. Authors reach this conclusion based on the expression of a reporter line, Drs-GFP. The authors speculate that this difference may reflect differential expression of an immune pathway component, as tracheal terminal cells (ttcs) do not respond to forced expression of PRGP-LS. The authors then go on to show that, unlike the other cells of the tracheal system, terminal cells do not express PGRP-LC as reported by a GAL4 enhancer trap. Forced expression of PGRP-LC in terminal cells resulted in reduced branching, cell damage and features of the cell death program. These effects could be suppressed by depletion of AP-1 or Foxo transcription factors. Authors show that Foxo plays a negative role in branching of ttcs, with ectopic branching occurring upon RNAi (or under hypoxic conditions). The authors speculate that immune privilege of the ttcs may have evolved to permit Foxo regulation of ttc branching. Strengths: The authors provide compelling genetic data that support their overall conclusions. Weaknesses: FC do not appear to express DRS reporter in Figure 1 or elsewhere, raising the question of whether fusion cells are also immune privileged. Fig 5, TRE_RFP expression, is convincing in wt ttc, but not in ttc o/x PGRP-LCx Summary: In this study, Bossen et al. looked at the immune status of the tracheal terminal cells (TTCs) in Drosophila larvae. The authors propose that these cells do show PGFP-LCx expression and, hence, lack immune function. Artificial overexpression of the PGRP-LCx in the TTCs causes these cells to undergo apoptosis. Strengths: Only a few groups have tried to look at the immune status of the trachea, though we know that AMPs are expressed there after infection. This exciting study attempts to understand the differences in the tracheal cells that do not produce AMPs upon infection. Weaknesses: The reason why the TTCs have some immune privilege still needs to be completely clear. Whether the phenotype is cell autonomous or contributes to the cellular immune system is not evaluated. As we know, crystal cells also maintain oxygen levels in larvae; whether in the absence of a terminal trachea, the crystal cells have any role is not explored. My particular comments on the figures are as follows: (1) In Figure 2, the PGRP-LCx signal should be quantified as done for Drosomycin GFP, as shown in Figure 1. - The authors have now done this. (2) In Fig 2F and G are the larvae infected? If not, what happens to PGRP-LCx expression post Ecc15 infection? - The authors have answered this question, saying infection has no effect on TTCs' Dr-GFP expression. (3) Is the effect of overexpression of LCx exaggerated post-infection? In particular, when it comes to the escape phenotype. - This was not done; the infection experiment was done with PGRP-LE overexpression. (4) Does overexpression of anti-apoptotic genes in TTC and PGRP-LCx rescue the TTC branching? - This was not done. (5) Have the authors tried to rescue the larvae with shallow food? - This was not done. (6) Is there any effect on the circulating hemocytes or lymph gland in the PGFRP-LCx overexpressing animals? - This was not done. Summary: The authors report that tracheal terminal cells (TTCs) in Drosophila do not activate innate immunity following bacterial infection, and attribute this to the absence of PGRP-LCx expression in these cells. Forced activation of the Imd pathway in TTCs leads to JNK-mediated cell death and reduced tracheal branching. The authors propose that this immune-privileged status preserves Foxo-dependent structural plasticity, which is essential for TTCs to respond to changing environmental conditions such as hypoxia. Strengths: The revised manuscript represents a meaningful improvement over the initial submission. The addition of multiple antimicrobial peptide reporters substantially strengthens the key observation that TTCs do not mount a humoral immune response upon infection, moving beyond reliance on the Drs-GFP reporter alone. The mechanistic dissection of the cell death pathway - demonstrating roles for JNK, AP-1, and Foxo downstream of ectopic PGRP-LCx activation - is well-executed and provides solid mechanistic insight. The inclusion of a second, independent UAS-PGRP-LCx line with a milder phenotype adds useful calibration. The hypoxia sensitivity assays provide physiological context, and the discussion of the gradient hypothesis, while based on qualitative observation, is logically reasoned and addresses a legitimate alternative interpretation. Weaknesses: The primary remaining concern is that the absence of PGRP-LCx expression in TTCs is supported by a single GAL4 enhancer trap line, without independent validation by complementary methods such as in situ hybridization, antibody staining, or reanalysis of publicly available single-cell transcriptomic data. The authors acknowledge this limitation transparently. While the convergent evidence from infection experiments - in which neither the Drs-GFP reporter nor the PGRP-LCx-Gal4 line shows TTC activation - lends indirect support, orthogonal confirmation would more definitively establish this mechanistic claim. Additionally, the finding that Dcp-1 cleavage occurs in non-TTC tracheal cells as well suggests that Imd-mediated apoptotic signaling is not uniquely restricted to TTCs, and the Discussion could more explicitly address what distinguishes the TTC response in terms of degree or cellular context. The following is the authors’ response to the original reviews. Public Reviews: Reviewer #1 (Public review): Summary: In their manuscript entitled "Terminal tracheal cells of Drosophila are immune privileged to maintain their Foxo-dependent structural plasticity", Bossen and colleagues determine that the terminal cells of the tracheal system differ from other larval tracheal cells in that they do not typically show an Imd-dependent immune response to fungal and viral infections. The authors reach this conclusion based on the expression of a reporter line, Drs-GFP. The authors speculate that this difference may reflect differential expression of an immune pathway component, as tracheal terminal cells (TTCs) do not respond to forced expression of PRGP-LS. The authors then go on to show that, unlike the other cells of the tracheal system, terminal cells do not express PGRP-LC as reported by a GAL4 enhancer trap. Forced expression of PGRP-LC in terminal cells resulted in reduced branching, cell damage, and features of the cell death program. These effects could be suppressed by the depletion of AP-1 or Foxo transcription factors. The authors show that Foxo plays a negative role in the branching of TTCs, with ectopic branching occurring upon RNAi (or under hypoxic conditions). The authors speculate that the immune privilege of the TTCs may have evolved to permit Foxo regulation of TTC branching. Strengths: The authors provide compelling genetic data. Weaknesses: (1) The authors state that after infection 34% of larvae were not GFP+ as defined by the detection of Drs-GFP in dorsal branches. The authors should clarify if these larvae are completely without response to infection, with no Drs-GFP in dorsal trunks and or other tracheal branches. If these larvae are entirely unresponsive, could authors indicate why this might be? Also, at this point in the manuscript, the authors are somewhat misleading regarding TTC expression of Drs-GFP - they should state at this point that there are some TTCs that do express Drs-GFP, and also should address their prior study of Drs-GFP induction which does not claim exclusion of TTC Drs-GFP expression. GFP– indicates the absence of detectable fluorescence in regions proximal to the TTCs (dorsal branch and fusion cells). Our analysis specifically focused on these regions and did not assess fluorescence in other parts of the tracheal system. Therefore, the reported 34% of larvae classified as GFP– does not imply a complete absence of response in these animals; rather, no fluorescence was detected within our defined region of interest. To clarify how fluorescence in TTCs was quantified, we have added a schematic (new Fig. 1F). In addition, new Fig. S1 illustrates that AMP reporter activation frequently occurs in other tissues. Our observations are consistent with earlier reports. In the original description of the AMP reporter lines, Tzou et al. (2000; https://doi.org/10.1016/S1074-7613(00)00072-8) reported that “only a fraction of the flies or larvae exhibited fluorescence in surface epithelia, and the proportion of GFP-expressing animals was variable from one culture vial to the next. In addition, fluorescence was rarely distributed throughout the whole tissue and was limited to restricted areas of the epithelium,” suggesting that AMP reporter activation can occur locally rather than uniformly across tissues. In a previous study (https://doi.org/10.1186/1471-2164-9-446), we reported that airway epithelial cells, including the finest tracheal endings on target organs, can activate drosomycin transcription following infection. However, that study focused specifically on infected larvae. Importantly, it did not quantify the frequency of reporter activation or analyze TTC-specific phenotypes. As such, those statements should not be interpreted as implying uniform or ubiquitous reporter activation across all tracheal cells. (2) The authors describe the terminal cell phenotype as "shrunken" but this implies loss of size or pruning, however, it is not clear whether the defects could equally be due to lack of growth or slower growth. We omitted the term “shrunken” in the present manuscript to avoid potential misinterpretation. (3) Figure 1 suggests that GFP+ dorsal branches are not uniform in their expression of Drs-GFP, it seems more patchy. The authors should define the fraction of dorsal branch cells that are Drs-GFP positive. Also, are fusion cells Drs-GFP positive? We included a schematic illustrating our quantification approach (new Fig. 1F). We also revised the wording to clarify that GFP+ animals include fluorescence not only in the dorsal branch (DB) but also in fusion cells (FCs), i.e., structures located between the dorsal trunks and the terminal tracheal cells (TTCs). Any structure in proximity to the TTCs that shows GFP expression was scored as GFP+. In most cases, GFP expression was observed in the dorsal fusion cells. (4) Drs-GFP expression is largely absent from terminal cells; however, a still significant # of terminal cells show expression (8%). Authors argue that PRGP-LC expression is absent based on a GAL4 transgenic line. If this line reflects endogenous PRGP-LC expression, should there not be 8% positive TTCs? Or is the 8% Drs-GFP expression independent of the IMD receptor? We detected PGRP-LE expression in approximately 3% of epithelial tracheal cells that expressed Drs after infection (Fig. 3F,G). This observation suggests that Drs activation can occur through a mechanism independent of PGRP-LCx. We have incorporated this finding into both the Results and Discussion sections. (5) Figure 2: the authors state that TTCs are negative even with induced PRGP-LE expression - should there not be at least 8% that are positive? We included infection of the PGRP-LE overexpression and could see Drs-GFP expression in 3 % of the cases, which we did not see without infection. (6) The authors compare PRGP-LC expression to induction of cell death by expression of reaper and hid. Reaper and Hid had stronger effects and eliminated TTCs. See cleavage of caspase Dpc-1 in PRGP-LC expressing cells. Is caspase cleavage always diagnostic of apoptosis or could the weaker than rpr/hid phenotype imply a different function? We have included the potential non-apoptotic functions of Dcp-1 in the Discussion. The weaker phenotype observed could therefore be explained by a non-apoptotic role of Dcp-1. (7) Drs-GFP expression is said to be "completely" absent from tracheal terminal cells when the entire tracheal system is expressing PGRP-LE. We have revised the wording accordingly. (8) Figure 5, TRE_RFP expression, is not convincing that it is higher or in terminal cells. https://doi.org/10.7554/eLife.102369.1.sa2 We have revised the wording in line 230. Reviewer #2 (Public review): Summary: In this study, Bossen et al. looked at the immune status of the tracheal terminal cells (TTCs) in Drosophila larvae. The authors propose that these cells do show PGFP-LCx expression and, hence, lack immune function. Artificial overexpression of the PGRP-LCx in the TTCs causes these cells to undergo apoptosis. Strengths: Only a few groups have tried to look at the immune status of the trachea, though we know that AMPs are expressed there after infection. This exciting study attempts to understand the differences in the tracheal cells that do not produce AMPs upon infection. Weaknesses: The reason why the TTCs have some immune privilege still needs to be completely clear. Whether the phenotype is cell autonomous or contributes to the cellular immune system is not evaluated. As we know, crystal cells also maintain oxygen levels in larvae; whether in the absence of terminal trachea, the crystal cells have any role is not explored. https://doi.org/10.7554/eLife.102369.1.sa1 In addition to the Drs-GFP reporter line, we performed new infection experiments using additional antimicrobial peptide reporters to further support our observations. While these experiments confirm the humoral immune response, they do not address the mechanisms underlying the apparent immune privilege. Our analysis therefore focuses specifically on the humoral immune response and does not allow conclusions regarding potential contributions of the cellular immune system, including crystal cells, to maintaining oxygen levels in animals with impaired TTCs. Notably, complete loss of TTCs is lethal, as demonstrated by TTC ablation using hid;rpr expression (Fig. 4F). Reviewer #3 (Public review): Summary: The authors report that tracheal terminal cells (TTCs) in Drosophila do not activate innate immunity following bacterial infection. They attribute this to the lack of expression of PGRP-LCx in these cells. Forced activation of the Imd pathway in TTCs leads to cell death and a reduction in tracheal branching. The authors propose a mechanism for cell death induction via pathways involving JNK, AP-1, and foxo. They suggest that the suppression of innate immunity in TTCs may serve to maintain their plasticity, preparing them for responses to hypoxic conditions. Strengths: (1) The study addresses the understudied area of immune privilege in innate immunity, providing a potentially important example in Drosophila TTCs. (2) The molecular characterization of the cell death pathway induced by forced Imd activation is well-executed and provides solid mechanistic insights. (3) The authors draw interesting parallels between Drosophila TTCs and mammalian endothelial cells, suggesting broader implications for their findings. Weaknesses: (1) The core premise of the study - that TTCs do not activate innate immunity following bacterial infection - relies heavily on a single readout (Drs reporter). Additional markers of immune activation would strengthen this crucial claim. We included new experiments using additional antimicrobial peptide reporter genes that show results similar to those obtained with the Drs-GFP reporter (new Fig. 1). (2) The evidence for the lack of PGRP-LCx expression in TTCs is based on a single GAL4 reporter line. Given the importance of this observation to the authors' model, validation using alternative methods would be beneficial. Although we were not able to include alternative methods to further confirm our hypothesis, we performed additional infection experiments. Upon bacterial infection, we observed a strong increase in GFP fluorescence throughout the animal and in many other tissues, while still detecting no response in the TTCs. These results further support our hypothesis. (3) The phenotypes observed upon forced activation of the Imd pathway in TTCs, while intriguing, may be influenced by non-physiological levels of pathway activation. The authors should address this potential caveat and consider examining the effects of more moderate pathway activation. https://doi.org/10.7554/eLife.102369.1.sa0 We used two independent UAS-PGRP-LCx lines located on different chromosomes. One line (III) produced a stronger phenotype than the other (II). We clarified this point in the Results section (Fig. 4C,D) and added supplementary data (new Fig. S2) showing that both lines produce comparable phenotypes when expressed using an alternative tracheal driver. The epithelial thickening observed follows the same pattern as the phenotype detected in TTCs, indicating that even moderate pathway activation leads to similar effects. However, we acknowledge that this represents ectopic pathway activation and therefore likely reflects a non-physiological level of signaling. Recommendations for the authors: Reviewer #2 (Recommendations for the authors): My particular comments on the figures are as follows: (1) In Figure 2, the PGRP-LCx signal should be quantified as done for Drosomycin GFP, as shown in Figure 1. We agree and have added a quantification. (2) In Figure 2F and G are the larvae infected? If not, what happens to PGRP-LCx expression post Ecc15 infection? We also included infected larvae to test whether infection induces GFP expression in TTCs. However, GFP expression was never observed in TTCs, although overall fluorescence increased in other tissues. (3) Is the effect of overexpression of LCx exaggerated post-infection? In particular when it comes to the escape phenotype. We induced mild Imd pathway activation by expressing PGRP-LE using a tracheal driver active in all tracheal cells, including TTCs, for 24 hours. In addition, these larvae were infected and their sensitivity to hypoxia was assessed. Animals expressing PGRP-LE in the trachea showed increased sensitivity to hypoxia, which was further enhanced following infection. (4) Does overexpression of anti-apoptotic genes in TTC and PGRP-LCx rescue the TTC branching? This point was not addressed. (5) Have the authors tried to rescue the larvae with shallow food? This point was not addressed. (6) Is there any effect on the circulating hemocytes or lymph glands in the PGFRP-LCx overexpressing animals? This point was not addressed. Reviewer #3 (Recommendations for the authors): The authors present an intriguing model of immune privilege in Drosophila tracheal terminal cells (TTCs). This model is built upon three key pillars: (1) the absence of innate immune activation in TTCs, (2) the lack of PGRP-LCx expression in TTCs, and (3) the induction of cell death when innate immunity is activated in TTCs. However, the experimental evidence supporting each of these critical points requires substantial strengthening. The reviewer recommends the following improvements and additional experiments to address these core issues: (1) Innate immune activation in TTCs: Evaluate the expression of additional antimicrobial peptide reporters to provide a more comprehensive assessment of innate immune activation in TTCs. In addition to the Drs-GFP reporter line, we performed new infection experiments using other antimicrobial peptide reporters to confirm our results. (2) PGRP-LCx expression in TTCs: Validate the PGRP-LCx-GAL4 line used in the study to ensure it accurately reflects endogenous PGRP-LCx expression. Employ complementary techniques such as in situ hybridization and antibody staining to corroborate the absence of PGRP-LCx in TTCs. We also included infection experiments using PGRP-LCx-Gal4 larvae. Infection did not trigger GFP expression in TTCs. However, the overall PGRP-LCx expression pattern observed in other larval tissues supports that the results reflect endogenous PGRP-LCx expression. (3) Cell death induction upon immune activation in TTCs: Address the possibility that the observed cell death is an artifact of strong, forced Imd pathway activation. To do that, perform control experiments activating the Imd pathway in non-TTC tracheal cells to determine if cell death is specific to TTCs. Use broader tracheal drivers (e.g., ppk4-GAL4 or btl-GAL4) to activate the Imd pathway and verify if cell death is indeed restricted to TTCs. We included results from PGRP-LCx overexpression using the tracheal driver ppk4-Gal4 and stained for the apoptosis marker Dcp-1 (new Fig. S3). We observed increased Dcp-1 signal in dorsal trunk cells, indicating that PGRP-LCx-mediated Dcp-1 cleavage is not restricted to TTCs. Ideally, generate a transgenic line expressing physiological levels of PGRP-LCx in TTCs and demonstrate that bacterial infection induces cell death specifically in TTCs through the proposed pathway. The reviewer acknowledges the complexity of this experiment but believe it would significantly strengthen the authors' conclusions. We did not generate a new transgenic line but instead used an alternative UAS-PGRP-LCx line (II), which exhibits a milder phenotype. This has now been clarified more prominently in the Results section (Fig. 4C,D). Additionally, we performed further experiments showing an epithelial thickening phenotype whose severity depends on the UAS-PGRP-LCx line used (new Fig. S2). In addition to the above major points (4) Quantitative data presentation: Provide quantitative analyses for the results presented in Figures 2 and 3J-K to allow for a more rigorous evaluation of the data. We included a quantitative analysis of the results shown in Fig. 2 (now presented in new Fig. 3). In addition, we added quantification of fluorescence in the TTCs of infected larvae. (5) Alternative hypothesis: Consider and address an alternative explanation for the lack of innate immune activation in TTCs: the potential gradient of bacterial ligands from proximal trachea to distal TTCs. If this hypothesis is correct, one might expect to see a gradient of Drs expression correlating with the distance from the proximal trachea. Addressing this possibility would strengthen the authors' proposed model. We now included the following paragraph as part of the discussion section. “An alternative explanation for the observed lack of an immune response in TTCs could be their maximal distance from the spiracles. In this scenario, a gradient of bacterial inducers along the tracheal system might be expected, resulting in a gradual decrease in immune activation from the spiracles toward the TTCs. However, this is not what we observed. In tracheae that displayed an immune response, the response was largely homogeneous along the entire length of the tracheal system, from the spiracles to the TTCs. Only at the transition to the TTCs did the immune response drop abruptly. This observation argues against the gradient hypothesis and suggests that TTCs are specifically excluded from the immune response.”